The Effect of SMN Gene Dosage on ALS Risk and Disease Severity - Université de Limoges Accéder directement au contenu
Article Dans Une Revue Annals of Neurology Année : 2021

The Effect of SMN Gene Dosage on ALS Risk and Disease Severity

Patrick Vourc'H
Mamede Carvalho
Monica Povedano
  • Fonction : Auteur
Markus Weber
  • Fonction : Auteur
Nazli Başak
  • Fonction : Auteur


Objective: The role of the survival of motor neuron (SMN) gene in amyotrophic lateral sclerosis (ALS) is unclear, with several conflicting reports. A decisive result on this topic is needed, given that treatment options are available now for SMN deficiency. Methods: In this largest multicenter case control study to evaluate the effect of SMN1 and SMN2 copy numbers in ALS, we used whole genome sequencing data from Project MinE data freeze 2. SMN copy numbers of 6,375 patients with ALS and 2,412 controls were called from whole genome sequencing data, and the reliability of the calls was tested with multiplex ligation-dependent probe amplification data. Results: The copy number distribution of SMN1 and SMN2 between cases and controls did not show any statistical differences (binomial multivariate logistic regression SMN1 p = 0.54 and SMN2 p = 0.49). In addition, the copy number of SMN did not associate with patient survival (Royston-Parmar; SMN1 p = 0.78 and SMN2 p = 0.23) or age at onset (Royston-Parmar; SMN1 p = 0.75 and SMN2 p = 0.63). Interpretation: In our well-powered study, there was no association of SMN1 or SMN2 copy numbers with the risk of ALS or ALS disease severity. This suggests that changing SMN protein levels in the physiological range may not modify ALS disease course. This is an important finding in the light of emerging therapies targeted at SMN deficiencies.
Fichier principal
Vignette du fichier
ana.26009.pdf (2.11 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03350820 , version 1 (11-04-2024)



Matthieu Moisse, Ramona Zwamborn, Joke Vugt, Rick Spek, Wouter Rheenen, et al.. The Effect of SMN Gene Dosage on ALS Risk and Disease Severity. Annals of Neurology, 2021, 89 (4), pp.686-697. ⟨10.1002/ana.26009⟩. ⟨hal-03350820⟩
24 Consultations
0 Téléchargements



Gmail Facebook X LinkedIn More